FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

R.I. Gen. Laws §5-19.1-11 says any pharmacy outside Rhode Island that ships, mails or delivers legend drugs, controlled substances or devices into the state is a nonresident pharmacy and must be licensed by the Department of Health. It must keep a valid home-state license and follow Rhode Island Board of Pharmacy regulations when dispensing to Rhode Island residents. Under 216-RICR-40-15-1 §1.7.3, licensure also requires: a Rhode Island agent for service of process (otherwise the Secretary of State is deemed the agent); disclosure of any final disciplinary actions by other licensing boards; and any information the Board requests. From December 1, 2024, the annual fee is at least $625, and license periods end September 30. The rule does not set a Rhode Island-licensed PIC requirement, a specific inspection-report requirement, or a separate nonresident sterile compounding permit.

The RI Department of Health website (health.ri.gov) blocked automated access, so the current application checklist (which may ask for inspection reports) was not reviewed; the statute and rule were confirmed. The rule was amended 4/12/2026.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Under 216-RICR-40-15-1 §1.8(A), a pharmacist/patient/prescriber relationship must exist to compound, and 'a practitioner's prescription shall be required for the compounding of all pharmaceuticals except as applied to Outsourcing Facilities'. Retail pharmacies may make only limited anticipatory batches based on a history of valid prescriptions. Pharmacists may not offer compounded preparations to other state-licensed persons or entities for resale, again except outsourcing facilities. The statute defines compounding as done on a practitioner's prescription or medication order 'based upon the individual needs of a patient', and says it 'shall only occur in the pharmacy where the drug or device is dispensed to the patient'. This matches FDA's patient-specific 503A position.

The rules do not use the phrase 'office use'; the 'no' rests on the universal prescription requirement and the outsourcing-facility-only exceptions. Hospital and institutional pharmacies may batch in anticipation of orders or approved protocols within their own institution.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

R.I. Gen. Laws §5-19.1-12 requires any person who manufactures legend drugs outside Rhode Island for distribution within the state to be licensed by the Department of Health. The statute defines 'manufacture' to include compounding (§5-19.1-2(q)). Rule 216-RICR-40-15-1 §1.15.1(A)(1)(c) bars shipping a manufacturer's prescription drug into Rhode Island unless each of its facilities is licensed there. It also requires FDA licensure, shipping only to the address on the purchaser's license, and making inspection reports available. The rules define 'outsourcing facility' (503B) and exempt outsourcing facilities from the prescription and no-resale limits on compounding. However, no rule text names a separate outsourcing-facility license, so the credential most clearly required is the manufacturer license.

That a license is required comes from the statute and rule text. That a 503B is licensed as a 'manufacturer', rather than under a separate outsourcing-facility or nonresident-pharmacy category, is inferred, because RIDOH's licensing pages (health.ri.gov) blocked automated access. A 503B that also dispenses patient-specific prescriptions into RI would also need a nonresident pharmacy license under §5-19.1-11.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Rhode Island is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

R.I. Gen. Laws 21-28-3.02(a) requires every person who prescribes, administers or dispenses any controlled substance in Rhode Island to obtain a registration from the Director of Health, and practitioners are automatically enrolled in the state PDMP as a condition of initial registration or renewal. The RIDOH rule (216-RICR-20-20-4, Sec. 4.5) repeats the requirement, sets registration intervals of no more than two years, requires applicants to comply with federal DEA registration requirements, and charges a filing fee set in the RIDOH fee rule (216-RICR-10-05-2). Applications go through the RIDOH Board of Pharmacy office.

Source older than 2 years - possibly stale: the rule text is the periodic refile effective 2022-01-04 (statute is current; it says 'annually' while the rule allows up to two years). Exemptions are in R.I. Gen. Laws 21-28-3.30 (not reviewed). Fee amount, per-location rule and the order relative to DEA were not confirmed. Applies to all prescribers, including APRNs and PAs.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

R.I. Gen. Laws Sec. 21-28-3.32(m) (repeated in Sec. 21-28-3.20(b)) requires the PDMP to be reviewed prior to starting any opioid, before refilling or initiating opioid therapy with an intrathecal pump, and at least every three months for patients on continuous opioid therapy for pain for three months or longer, with documentation in the record. Department of Health rule 216-RICR-20-20-4.4 likewise requires review before initially prescribing any opioid (including inpatient) and rechecks at least every three months during ongoing opioid treatment. Practitioners must also register with the PDMP as a condition of controlled substance registration; the Rhode Island Department of Health runs the program.

Source older than 2 years - possibly stale; Sec. 21-28-3.32 was last amended by P.L. 2021, ch. 90 and 91 (eff. June 25, 2021) and the DOH rule was amended 1/2/2020 - both are the currently posted versions. The rule summary came from a WebFetch reading of LII, which reported that PDMP review is tied to opioids only.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

216-RICR-40-15-1.9 (amended 12/8/2022) lets practitioners supply prescription samples to their patients and addresses automated and stock medications in certain settings, with drug utilization review and labeling requirements; it bars practitioner dispensing of controlled substances in emergency rooms and ambulatory surgery centers. A vendor summary says Rhode Island prescribers may dispense to their own patients without a permit and need a state controlled substance registration for controlled drugs, but the rule text reviewed does not state a general office-dispensing authority.

Check with the Rhode Island Department of Health, Board of Pharmacy. Source older than 2 years.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) A physician licensed only in another state may treat a Rhode Island patient only in narrow cases (federal employment, a one-time consultation requested by a Rhode Island physician, short volunteer or sports-team service), and may not consult remotely with a patient lacking a relationship unless a Rhode Island physician is present (R.I. Gen. Laws 5-37-16.2, per CCHP). (2) Board rules hold telemedicine to face-to-face standards, bar questionnaire-only prescribing and state that asynchronous evaluation without a contemporaneous real-time interactive exchange is not appropriate (216-RICR-40-05-1). (3) The Board of Medical Licensure and Discipline's telemedicine guidelines state that prescribing controlled substances without an established in-person physician-patient relationship is prohibited (except short-term prescribing by a covering physician), which reaches Schedule III drugs such as testosterone. (4) IMLC: passed, not yet implemented (implementation delayed).

The controlled-substance in-person statement comes from an undated Board guideline PDF (its references date from 2000-2001) that is still posted; the current RIDOH telemedicine web page repeats the general guidance but not the controlled-substance sentence. Source older than 2 years - possibly stale. The Board (https://health.ri.gov/licenses/physicians) may apply it differently in light of federal telemedicine rules. Section number 1.5.9 is as cited by CCHP; the telemedicine text was read in the rule itself.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

RIDOH's July 2024 guidance on medical spas and IV therapy businesses, prepared with the professional licensing boards, includes a scope-of-practice chart. For neuromodulators (Botox) it lists physicians, PAs (in collaboration with a physician), family-practice and adult-gerontology CNPs, dentists, and pharmacists with a valid prescription as permitted, and RNs, LPNs, electrologists and estheticians as not permitted. For dermal fillers only physicians are listed. The guidance also says a patient must be assessed by a RI-licensed physician, PA or CNP before any service, and that unlicensed persons may not perform any medical procedure.

Guidance dated 'Established: July 2024' (recorded as 2024-07-01). This is stricter than most states; confirm with RIDOH before relying on it for biostimulators/skin boosters, which the chart does not list separately.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

RIDOH's 2024 guidance says IV fluids are drugs that must be prescribed by a physician, PA or CNP for a specific patient and diagnosis after a history and physical exam documented in a medical record; the exam ideally occurs in person and a questionnaire alone is prohibited. Standing orders for RNs in this setting are unprofessional conduct, and patients may not select IVs from a menu. RNs may administer with a valid prescription; LPNs, EMTs, medical assistants and phlebotomists may not work in these businesses. Compounding requires an on-site physician or pharmacist (remote supervision prohibited), and walk-in or concierge IVs do not qualify for USP <797> immediate use. Off-site services need a home nursing care provider licence (with certificate of need), and mobile units need an organized ambulatory care facility licence.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

RIDOH's 2024 guidance says whether a med spa or IV business needs a health facility licence depends on its ownership, services and owners' licences. Licensees may form a professional service corporation (R.I. Gen. Laws ch. 7-5.1) and be exempt, but at least one owner must be able to perform the services offered (a nurse-owned PSC offering Botox must include a physician, PA or CNP owner). Otherwise an organized ambulatory care facility licence is required, and "leasing" a PSC to a management company to avoid licensure is treated as misrepresentation. Businesses may not control the physician's, PA's or CNP's medical judgment. Permit Health rates Rhode Island a moderate CPOM state.

HB 7721/SB 2459 (2026), reported pending, would add CPOM, MSO and ownership-reporting rules (per MedPath Compliance).

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

RIDOH's 2024 guidance chart lists laser hair removal as permitted for physicians, PAs, CNPs and electrologists who meet the training in R.I. Gen. Laws §5-32-21 (who may work without physician supervision), and not for RNs, LPNs or estheticians. Intense pulsed light and laser tattoo removal are listed for physicians and PAs only; radiofrequency skin tightening for physicians, PAs and estheticians. Ablative lasers (CO2, erbium) should be performed only by a physician or delegated to a trained PA; non-ablative devices may be delegated to trained CNPs or PAs.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

R.I. Gen. Laws §23-16.2-4 makes it unlawful to perform clinical or analytical laboratory services 'on specimens collected in this state', or to maintain a lab or collection station in Rhode Island, without a Department of Health license (two-year term). Exceptions in §23-16.2-3 cover hospital and physician labs testing only their own patients, approved public screening programs, limited-function tests and pharmacist testing. The chapter also has a section prohibiting the transmission of specimens to an unlicensed laboratory (§23-16.2-10).

Out-of-state labs: yes.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Rhode Island's rule. Rhode Island's lab regulator (CLIA state agency) is Rhode Island Dept. of Health, Division of Facilities Regulation (DOH.OFR@health.ri.gov, 401-222-2721). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) lists Rhode Island among states that restrict independent test ordering; not confirmed. Rhode Island requires a state license for any lab testing RI specimens. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Rhode Island is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

The Consumer PFAS Ban Act of 2024 (R.I. Gen. Laws ch. 23-18.18) lists cosmetics as a 'covered product' and bars manufacturing, selling or distributing covered products with intentionally added PFAS from Jan 1, 2027. Unavoidable trace PFAS in cosmetics from ingredient impurities, manufacturing, storage or packaging migration is not a violation. Artificial turf and outdoor apparel for severe wet conditions follow on Jan 1, 2029.

One 2026 compilation (Adherent) gives Jan 1, 2029 for cosmetics, but the statute text puts cosmetics in the Jan 1, 2027 covered-product ban. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.